Literature DB >> 8900110

Genotoxic drugs induce interaction of the c-Abl tyrosine kinase and the tumor suppressor protein p53.

Z M Yuan1, Y Huang, M M Fan, C Sawyers, S Kharbanda, D Kufe.   

Abstract

The function of the c-Abl protein tyrosine kinase is unknown. The present studies demonstrate that the antimetabolite 1-beta-D-arabinofuranosylcytosine (ara-C) induces binding of c-Abl and p53. Ara-C treatment of cells that express wild type or a dominant negative, kinase-inactive c-Abl(K-R) was associated with formation of c-Abl-p53 complexes and increased expression of the cyclin-dependent kinase (Cdk) inhibitor p21. However, down-regulation of Cdk2 by ara-C was found in cells expressing wild type c-Abl and not in cells expressing c-Abl(K-R) or those deficient in p53. Similar findings were obtained following treatment of cells with the alkylating agent methyl methanesulfonate (MMS). Cells that express the c-Abl dominant negative or are null for c-Abl exhibited partial abrogation of Cdk2 down-regulation and G1 arrest in response to MMS exposure. Cells lacking the c-abl gene also responded to ara-C and MMS with increases in p53 levels and induction of p21. These findings indicate that the cellular response to certain genotoxic drugs involves binding of c-Abl to p53 and down-regulation of Cdk2 by a c-Abl kinase/p53-dependent mechanism.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8900110     DOI: 10.1074/jbc.271.43.26457

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  16 in total

Review 1.  Molecular interaction map of the mammalian cell cycle control and DNA repair systems.

Authors:  K W Kohn
Journal:  Mol Biol Cell       Date:  1999-08       Impact factor: 4.138

2.  Stimulation of p53 DNA binding by c-Abl requires the p53 C terminus and tetramerization.

Authors:  Y Nie; H H Li; C M Bula; X Liu
Journal:  Mol Cell Biol       Date:  2000-02       Impact factor: 4.272

3.  Targeting of the c-Abl tyrosine kinase to mitochondria in endoplasmic reticulum stress-induced apoptosis.

Authors:  Y Ito; P Pandey; N Mishra; S Kumar; N Narula; S Kharbanda; S Saxena; D Kufe
Journal:  Mol Cell Biol       Date:  2001-09       Impact factor: 4.272

4.  c-Abl regulates p53 levels under normal and stress conditions by preventing its nuclear export and ubiquitination.

Authors:  R V Sionov; S Coen; Z Goldberg; M Berger; B Bercovich; Y Ben-Neriah; A Ciechanover; Y Haupt
Journal:  Mol Cell Biol       Date:  2001-09       Impact factor: 4.272

5.  Involvement of c-Abl, p53 and the MAP kinase JNK in the cell death program initiated in A2E-laden ARPE-19 cells by exposure to blue light.

Authors:  Barbro S Westlund; Bolin Cai; Jilin Zhou; Janet R Sparrow
Journal:  Apoptosis       Date:  2009-01       Impact factor: 4.677

6.  MUC1 oncoprotein blocks nuclear targeting of c-Abl in the apoptotic response to DNA damage.

Authors:  Deepak Raina; Rehan Ahmad; Shailendra Kumar; Jian Ren; Kiyotsugu Yoshida; Surender Kharbanda; Donald Kufe
Journal:  EMBO J       Date:  2006-08-03       Impact factor: 11.598

7.  Role for Lyn tyrosine kinase as a regulator of stress-activated protein kinase activity in response to DNA damage.

Authors:  K Yoshida; R Weichselbaum; S Kharbanda; D Kufe
Journal:  Mol Cell Biol       Date:  2000-08       Impact factor: 4.272

8.  c-Abl tyrosine kinase regulates the human Rad9 checkpoint protein in response to DNA damage.

Authors:  Kiyotsugu Yoshida; Kiyoshi Komatsu; Hong-Gang Wang; Donald Kufe
Journal:  Mol Cell Biol       Date:  2002-05       Impact factor: 4.272

9.  Werner syndrome protein phosphorylation by abl tyrosine kinase regulates its activity and distribution.

Authors:  Wen-Hsing Cheng; Cayetano von Kobbe; Patricia L Opresko; Kesha M Fields; Jian Ren; Donald Kufe; Vilhelm A Bohr
Journal:  Mol Cell Biol       Date:  2003-09       Impact factor: 4.272

10.  Tyrosine phosphorylation of Mdm2 by c-Abl: implications for p53 regulation.

Authors:  Zehavit Goldberg; Ronit Vogt Sionov; Michael Berger; Yaara Zwang; Ruth Perets; Richard A Van Etten; Moshe Oren; Yoichi Taya; Ygal Haupt
Journal:  EMBO J       Date:  2002-07-15       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.